OvaScience Inc. (NASDAQ:OVAS) fell 1.4% during trading on Monday . The stock traded as low as $5.47 and last traded at $5.58, with a volume of 354,548 shares traded. The stock had previously closed at $5.66.

A number of equities research analysts have weighed in on the stock. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of OvaScience in a report on Monday, April 25th. S&P Equity Research reduced their target price on shares of OvaScience from $10.82 to $8.83 in a report on Monday, March 21st. Credit Suisse Group AG reissued an “underperform” rating on shares of OvaScience in a report on Friday, March 25th. Finally, Leerink Swann reissued a “hold” rating and set a $7.00 target price (up from $6.00) on shares of OvaScience in a report on Sunday, May 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. OvaScience currently has a consensus rating of “Hold” and a consensus target price of $12.37.

The stock has a 50-day moving average price of $6.24 and a 200 day moving average price of $7.50. The stock’s market cap is $148.94 million.

OvaScience (NASDAQ:OVAS) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.08. The firm earned $0.15 million during the quarter, compared to analyst estimates of $0.14 million. During the same quarter last year, the business earned ($0.65) earnings per share. OvaScience’s quarterly revenue was up 630.0% on a year-over-year basis. Analysts forecast that OvaScience Inc. will post ($3.14) earnings per share for the current fiscal year.

In other news, Director Richard Aldrich acquired 36,095 shares of the firm’s stock in a transaction dated Friday, May 13th. The shares were acquired at an average cost of $6.94 per share, with a total value of $250,499.30. Following the acquisition, the director now directly owns 604,185 shares of the company’s stock, valued at $4,193,043.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michelle Dipp acquired 19,900 shares of the firm’s stock in a transaction dated Tuesday, May 10th. The shares were purchased at an average cost of $7.72 per share, for a total transaction of $153,628.00. Following the completion of the acquisition, the chief executive officer now directly owns 971,921 shares in the company, valued at $7,503,230.12. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in OvaScience stock. AWM Investment Company Inc. boosted its stake in OvaScience Inc. (NASDAQ:OVAS) by 1.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 116,352 shares of the company’s stock after buying an additional 1,352 shares during the period. AWM Investment Company Inc. owned approximately 0.43% of OvaScience worth $1,137,000 as of its most recent filing with the SEC.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.